Loading clinical trials...
Loading clinical trials...
A Drug-Drug Interaction, Single-arm, Open-label Study to Assess the Effect of Quinidine on the Pharmacokinetics of Orforglipron in Healthy Participants
Conditions
Interventions
Orforglipron
Midazolam
+1 more
Locations
1
United States
ICON
Salt Lake City, Utah, United States
Start Date
December 6, 2024
Primary Completion Date
February 5, 2025
Completion Date
February 5, 2025
Last Updated
February 28, 2025
NCT06716502
NCT07310264
NCT00090662
NCT06290258
NCT07483606
NCT07310901
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions